Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus Probiotic in Children With Drug Resistant Epilepsy
NCT05539287Phase 2Completed
- Sponsor
- Tanta University
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of live double combined lactobacillus in epilepsy (2 arms), sponsored by Tanta University. Primary endpoint: Effectiveness of Lactobacillus probiotics for controlling epileptic seizures at 6 months. Started Sep 2022; status: completed.
02
Drugs
live double combined lactobacillus
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05539287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05539287.